Q-omics provides the consensus-scored CHIC2 profile across patient tissues and cancer cell-line models. CHIC2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CHIC2 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, CHIC2 RNA expression shows 19,927 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where CHIC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHIC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHIC2 survival associations across molecular data types. CHIC2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHIC2 RNA expression–survival associations across cancer types. High CHIC2 expression shows unfavorable associations in ACC, HNSC, LGG, KIRP and UVM, but favorable associations in CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CHIC2 RNA expression.
This table summarizes CHIC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CHIC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHIC2 shows lower tumor expression in KICH, THCA and LUAD and higher tumor expression in HNSC, KIRC and COAD. The KICH box plot shows higher CHIC2 RNA expression in normal versus tumor tissue (log2 FC = −1.811, t-test p < 0.001).
This table shows molecular features associated with CHIC2 in patient tissues and cancer cell lines. In patient samples, CHIC2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHIC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
